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Hyun Min Jung, Brittany L Phillips and Edward KL Chan*Abstract
Background: While microRNAs (miRNAs) are extensively studied in post-transcriptional regulation of gene
expressions in many biological processes, cellular miRNA-mediated regulation of viral genes remains unclear. In particular,
the interplay between human papillomavirus (HPV) genes and miRNAs and how these interactions contribute to
HPV-associated cancers remain elusive.
Methods: Transient transfection of miR-375-mimic was used to compensate the loss-of-function of miR-375 in
HPV-positive cancer. Regulation of oncogenic molecules and their downstream molecules via miR-375 in
HPV-positive cancer was investigated using qRT-PCR, western blot, dual luciferase assay, indirect immunofluorescence
analysis. All experiments were conducted at least three times to achieve statistical significance determined by Student
t-test.
Results: In this study, we demonstrated how miR-375 negatively regulates HPV16 and 18 transcripts. We also found a
cellular protein, E6-associated protein (E6AP), directly regulated by miR-375. miR-375-mediated repression of HPV
transcripts and E6AP elevated major tumor suppressors p53, p21, and retinoblastoma protein 1 (RB). Cooperative
regulation of miR-375 targets along with the increase of tumor suppressors led to ~60% reduction of telomerase
reverse transcriptase (TERT) transcription followed by ~35% decrease of telomerase activity. Furthermore, miR-375-mediated
regulation of 14-3-3ζ contributes to decrease telomerase activity by altering nuclear translocation of TERT.
Conclusion: Taken together, miR-375-mediated suppression of multiple oncogenic components in HPV-associated
carcinogenesis generates a cumulative biological response to rescue key tumor suppressors and diminish telomerase
activity, which results in cell cycle arrest and cell proliferation inhibition.
Keywords: MicroRNA, miR-375, p21, Human papillomavirus, E6AP, TelomeraseIntroduction
MicroRNAs (miRNAs) are approximately 22 nucleotide
(nt) long small non-coding RNAs that play key roles in
differentiation and development by post-transcriptional
regulation of cellular genes [1]. Although typical miRNA-
mRNA interactions occur in the 3′ untranslated region
(UTR) of the target, coding sequences are also subjected
to miRNA binding. This binding directs translational re-
pression and mRNA degradation [2,3]. Over 1,000 human
miRNAs are predicted to regulate approximately 60% of* Correspondence: echan@ufl.edu
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unless otherwise stated.protein-coding genes, indicating their extensive functions
in many biological processes [4].
Human papillomaviruses (HPVs) are 8-kb double-
stranded DNA viruses that specifically target basal cells of
the epithelial mucosa [5]. HPV infection is implicated in
virtually all cervical cancers, ~90% of anal cancers, 30 ~ 60%
of oropharyngeal cancers, and ~40% of vaginal, vulvar,
and penile cancers [6]. HPV16 and HPV18 are the most
common HPV types associated with these aforemen-
tioned cancers [7]. High-risk HPVs closely linked to ma-
lignancies have developed strategies to evade the human
immune system. Examples include suppressing interferon-
α-inducible gene expression [8,9], and directly regulating
interferon signaling pathways by HPV E6/E7 [10,11].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mediated cancers, E6 and E7 coded by high-risk HPVs are
considered highly oncogenic [5,7,12-15].
Telomeres are specialized functional complexes that
maintain the integrity and stability of the genome by
protecting the ends of eukaryotic chromosomes [16]. A
telomere consists of hexanucleotide (TTAGGG) tandem
repeats, ending with a single stranded overhang that
forms telosomes with protein complexes [17]. In nor-
mally dividing somatic cells, telomeres shorten by about
60-150 bp with each cell division due to the DNA end
replication problem [18,19]. Then telomeres are shortened
to a certain length, cell cycle arrest and proliferation fail-
ure occur, inducing cellular senescence [20]. Tumors can
overcome this regulation by activating telomerase, a ribo-
nucleoprotein complex enzyme with reverse transcriptase
activity that maintains a constant telomere length [21,22].
Enhanced telomerase activity is observed in most malig-
nant tumors (~90%) but the mechanisms underlying its
regulation are not fully understood [23].
In the present study, we showed that miR-375 sup-
presses high-risk HPV E6 and E7, and E6AP. Moreover,
the effect of these regulations was incorporated with
previous findings of miR-375 targets shown in other
cancer cells [3,24]. This study demonstrates how miR-
375 behaves as a tumor suppressor miRNA by rescuing
major tumor suppressors, suppressing oncogenic com-
ponents, and thus regulates cell cycle and telomerase
activity.
Results
miR-375 targets HPV type 16 and 18 transcripts and
suppresses E6 and E7 expression
While searching for oncogenic targets regulated by miR-
375 in addition to cancerous Inhibitor of PP2A (CIP2A)
in our previous study [3], we investigated potential inter-
actions between miR-375 and HPV16 transcripts. We
used the program RNA22 to predict these potential in-
teractions because this algorithm relies on sequence
complementarity between miRNA and target RNA re-
gardless of interaction location within the transcript
[25]. A total of five putative miR-375 binding sites were
predicted, two in the E7 region and three in the E1 re-
gion (Figure 1A). We generated FL reporter constructs
to determine the direct interactions between miR-375
and these predicted sites. We inserted E7/E1 region
downstream of the FL reporter (Figure 1B). Site-directed
mutagenesis generated mutations in the seed sequences
of five miR-375 binding sites (Figure 1A and 1B). Co-
transfection of FL-E7/E1 reporter with miR-375-mimic
showed 25-30% repression, and the repression effect was
abolished when the five miRNA-mRNA interactions were
disrupted (FL-E7/E1-m1-5, Figure 1B). Co-transfection of
FL-E7 with miR-375-mimic resulted in ~20% reduced FLactivity, but mutation of individual binding sites (m1 or
m2) did not rescue this repression effect (Additional file 1:
Figure S1A). Similar results were observed when FL-E1
was co-transfected with miR-375-mimic. FL activity was
significantly reduced (~20%) by miR-375 but mutations
on single miR-375 binding sites (m3 to m5) did not rescue
this repression (Additional file 1: Figure S1B). These
results indicate that the five binding sites more likely
produce a synergistic effect, instead of an additive ef-
fect, to suppress HPV16 transcript expression.
In order to measure the repression effect of miR-375
on endogenous HPV16 transcripts, two HPV16-positive
cancer cell lines, cervical cancer line SiHa and oropha-
ryngeal cancer line UPCI:SCC090 (hereafter SCC090),
were transfected with miR-375-mimic. E6 and E7 mRNA
expression were measured 48 h post-transfection using
Taqman quantitative PCR. Interestingly, both E6 and E7
transcript levels were reduced ~60% in SiHa cells
transfected with 25 nM of miR-375-mimic molecules
(Figure 1C). In SCC090 cells, neither 50 nor 100 nM of
miR-375-mimic was sufficient to reduce E6 or E7 levels.
Significant reduction of both E6 and E7 (~30%) was ob-
served when a higher concentration (200 nM) of miR-
375-mimic was used for transfection (Figure 1D). This
higher dose requirement in SCC090 cells could be ex-
plained by the dramatically higher HPV16 transcript
levels present compared to SiHa cells (Additional file 1:
Figure S2). E6, E7, and E6/E7/E1 transcripts were detected
in both cell lines, as well as in three human oropharyngeal
tumors (T1-T3) (Additional file 1: Figure S2). Although
four E6 mRNA splicing isoforms were detected as re-
ported previously [26], the miR-375-mediated repression
observed here is not affected since the putative miR-375
binding sites are located on E7 and E1 region. Interest-
ingly, miR-375-mimic transfection in HeLa cells (HPV18
positive) also reduced both E6 and E7 transcript levels
by ~50% (Figure 1E). Bioinformatics suggested that
HPV18 also have putative binding sites for miR-375
(data not shown). Transfection of miR-375 inhibitor did
not affect the expression of HPV16 and HPV18 transcript
expressions in SiHa, SCC090, and HeLa cells because en-
dogenous miR-375 levels in these cells were already ex-
tremely low (~32 Ct values by real-time PCR). However,
the functionality of the miR-375 inhibitor was clearly
demonstrated in the transfection of MCF7 cells which had
moderate expression of miR-375 (see in the following
figures). Taken together, these data indicate that miR-375
directly regulates HPV16 and HPV18 transcripts.
miR-375 directly targets and represses E6AP
Prediction of miR-375 binding site in the E6AP 3′UTR
was performed by TargetScan [27]. The 3′UTR of E6AP
was cloned downstream of FL reporter and site-directed
mutagenesis of four nucleotides in the seed binding sites
Figure 1 miR-375 targets HPV type 16 and 18 transcripts and suppresses E6 and E7 expression. (A) Five putative miR-375 binding sites on
HPV16 transcript sequence. Integrated HPV16 viral gene produces polycistronic transcripts consisting of E6, E7, and E1. Two putative sites on E7
region and three putative sites on E1 region of HPV16 transcript were predicted to interact with miR-375. Lines between nucleotides of HPV16
sequence and miR-375 are typical Watson–Crick interactions (A-U and G-C, respectively), and colons are weak, nontypical base-pair interactions.
Corresponding specific seed binding site mutants were generated for dual luciferase reporter assays. (B) FL repression effect was analyzed with
FL construct that contains both E7 and E1 regions. Five putative miR-375 binding sites were mutated to examine their direct interaction. Cells
were cotransfected with miR-375-mimic or non-specific control (NS). Renilla luciferase was used as an internal control to normalize FL activity
expression. Results were compared to NS control transfected cells for statistical analyses. (C) Real-time PCR analyses of endogenous E6 and E7
mRNA levels in SiHa (HPV16-positive cervical cancer cell line) transfected with miR-375-mimic. (D) Measurement of endogenous E6 and E7 mRNA
level in UPCI:SCC090 (HPV16-positive oropharyngeal cancer cell line) transfected with miR-375-mimic. Final concentration of 25 nM was used for
miR-375 inhibitor and NS control, and 50, 100, 200 nM were used for miR-375-mimic transfection. (E) Expression changes in E6 and E7 mRNA in
HeLa (HPV18-positive cervical cancer) after miR-375-mimic transfection. Final concentration of 25 nM was used for miR-375 inhibitor, miR-375-mimic,
and NS control for transfection. White and black bars indicate E6 and E7 mRNA levels, respectively. Results are expressed as mean ± SD from at least
three independent experiments. **p < 0.01 and ****p < 0.0001.
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interaction (Figure 2A). The dual luciferase reporter sys-
tem was used to investigate the direct interaction be-
tween E6AP 3′UTR and miR-375. A significant decrease
in FL activity (30%, p <0.01) was observed. This direct
repression effect was abolished by mutating the seed
binding site (Figure 2B). SiHa cells were used in the follow-
ing experiments as HPV16-positive cells due to the lower
concentration of miR-375-mimic required for HPV16 sup-
pression in SiHa compared to SCC090 cells (Figure 1).
Transfection of miR-375-mimic (25 nM) in SiHa cells re-
duced ~50% of E6AP protein levels (Figure 2C) and ~30%
of endogenous E6AP mRNA (Figure 2D). Transfection of
miR-375-mimic (25 nM) in HeLa cells reduced ~30% of
E6AP protein and ~40% of E6AP mRNA (Figure 2E and 2F).
These results demonstrate that miR-375 directly regulates
E6AP by interacting with the 3′UTR.
miR-375 increases p21, p53, and RB in HPV16- and
18-positive cancer
HPV-positive cervical or oropharyngeal cancers contain
wild type p53 and/or RB, and inactivation of these tumor
suppressors are driven by E6 and E7 proteins produced
from high-risk HPVs [28-30]. Cellular E6AP forms a
complex with E6, inhibiting p53 by ubiquitin-dependentFigure 2 miR-375 directly targets and represses E6AP. (A) Sequence o
was generated by disrupting base paring of four nucleotides, positions 2 to
reporter. Results were compared with FL-E6AP co-transfected with NS cont
transfected with miR-375 inhibitor, -mimic, or NS control were analyzed by
50%, 100% amounts of untreated cell lysates were included to calibrate the
levels of E6AP from SiHa cells transfected with miR-375 inhibitor, -mimic, o
HeLa cells transfected with miR-375 inhibitor, -mimic, or NS control was an
were measured 48 h post-transfection. Results are expressed as mean ± SDdegradation [31]. E7 degrades RB, activating cell prolifer-
ation genes [32,33]. Therefore, SiHa and HeLa cells are
appropriate representative model systems for studying
HPV16 and HPV18, because they are known to contain
wild type p53 and RB, respectively [28]. To examine the
downstream effect of miR-375-mediated regulation of
HPV transcripts and E6AP, we examined the expression
of crucial tumor suppressors related to these pathways.
In SiHa cells, miR-375-mimic transfection increased p53
and RB protein levels (Figure 3A). Interestingly, p21,
which is a major downstream player in p53-mediated
tumor suppression, showed dramatic protein level ele-
vation after miR-375-mimic transfection (Figure 3A).
p21 transcript levels significantly increased in cells with
miR-375-mimic transfection (Figure 3B) and this increase
could be explained by p53 protein level elevation
(Figure 3A). The increase of p53 and RB proteins was not
a result of transcriptional activation of corresponding
genes, which indicates minimal changes in de novo pro-
teins (Figure 3B). Therefore, it is more reasonable to inter-
pret the increase as rescue of p53 and RB proteins by the
miR-375-mediated suppression of E6 and E7 (Figure 1). A
significant decrease in cell proliferation (~50%) was ob-
served after miR-375-mimic transfection, compared to
cells transfected with NS control (Figure 3C). These re-
sults showed that the rescue of tumor suppressors byf putative miR-375 binding site in the 3′UTR of E6AP. E6AP 3′UTR-mut
5. (B) Relative FL repression effects of miR-375 on the FL-E6AP
rol for statistical analysis. (C) E6AP protein level changes in SiHa cells
Western blot. Tubulin expression was used as internal control. 25%,
semiquantitative analysis. (D) In parallel, relative endogenous mRNA
r NS control were measured using qRT-PCR. (E) E6AP protein level in
alyzed by Western blot. (F) Endogenous E6AP mRNA level in HeLa cells
from at least three independent experiments. **p < 0.01.
Figure 3 miR-375 increases p21, p53, and RB in HPV16- and 18-positive cancer. (A) Protein levels of p21, p53, and RB in SiHa cells
transfected with miR-375 inhibitor, -mimic, or NS control were measured by Western blot analysis. 25%, 50%, 100% amounts of untreated cell
lysates were included to calibrate the semiquantitative measurement. (B) Relative endogenous mRNA levels of p21, p53, and RB were measured in
SiHa cells transfected with miR-375 inhibitor, -mimic, or NS control using qRT-PCR. (C) One hundred thousand SiHa cells were seeded on 24-well plate
and the number of cells was counted by trypan blue exclusion staining assay 48 h post-transfection. (D) Protein levels of p21, p53, and RB in HeLa cells
transfected with miR-375 inhibitor, -mimic, or NS control were measured by Western blot analysis. (E) Relative p21 mRNA levels were measured in HeLa
cells transfected with miR-375 inhibitor, -mimic, or NS control. (F) Trypan blue exclusion staining assay was used to analyze the proliferation rate of
HeLa cells 48 h post-transcfection. (G) Flow cytometry analysis demonstrates G1 arrest of SiHa cells 48 h after transfection with miR-375-mimic compared
to miR-375 inhibitor or NS control. (H) Protein levels of CIP2A, p53, and p21 in SiHa cells transfected with si-CIP2A and/or si-p53 were measured by
Western blot analysis. (I) Protein levels of CIP2A, p53, and p21 in SiHa cells transfected with si-p53 and/or miR-375-mimic were measured by Western
blot analysis. (J) mRNA levels of p21 in SiHa cells transfected with si-p53 and/or miR-375-mimic were measured by qRT-PCR. The concentrations of
siRNA or miRNA used in panels H, I, and J were 10 nM and 25 nM, respectively. Results are expressed as mean ± SD from three independent
experiments. *p < 0.05, ***p < 0.001, and ****p < 0.0001.
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proteins led to reduced proliferation of HPV-positive
cancer cells.
Similar results were observed in HeLa cells. p21, p53,
and RB protein levels dramatically increased and p21
mRNA levels significantly elevated in HeLa cells 48 h
post-transfection of miR-375-mimic (Figure 3D and 3E).
We observed about 40% reduction of cell proliferation
after 48 h (Figure 3F). p21, p53, and RB are important
cell cycle regulators [34-36]. Thus, flow cytometry was
used to measure the cellular DNA content of cells trans-
fected with miR-375-mimic or inhibitor to determine
the cell cycle status. We observed a dramatic increase in
G1-arrested cells and a reduced amount of S and G2/M
phase cells 48 h post-transfection of miR-375-mimic,
compared to NS control (~23%, p < 0.001, Figure 3G).
Together, these results explain how miR-375 inhibits
proliferation of these HPV-positive cancer cells.miR-375 control on CIP2A-MYC pathway also contributes
to p21 elevation
In our previous study, we identified CIP2A as a target of
miR-375 in oral cancer [3]. CIP2A protects MYC from
dephosphorylation by PP2A and as a result prevents its
proteolytic degradation [37], and MYC is a transcriptional
repressor of p21 [38]. Thus, the potential involvement
of miR-375 regulation of CIP2A-MYC in this pathway
was investigated. We used siRNAs to knockdown either
CIP2A or p53 to examine to effects of these proteins on
p21 expression. Knockdown of p53 dramatically reduced
p21 protein levels (76% reduction, Figure 3H). We also
found a potential relevance between CIP2A and p53.
Silencing CIP2A led to 33% increase of p53 (Figure 3H)
and knockdown of p53 increased CIP2A to 40-80%
(Figure 3H and 3I). While how p53 regulates CIP2A is un-
known, it is clear that CIP2A plays a protective role for
MYC [37], and that MYC impairs transactivation of p53
in human cancer cells [39-41]. Interestingly, knockdown
of CIP2A increased p21 by 69% (Figure 3H), and increase
of p21 by CIP2A silencing was also observed in p53-
knockdown cells (a slight increase from 24% to 33%,
Figure 3H). This result indicated that induction of p21
by miR-375 is mainly due to the elevation of its major
transcriptional activator p53, and miR-375-mediated re-
duction of its transcriptional repressor MYC also con-
tributes to p21 increase.
The effect of miR-375-mimic was examined in p53-
knockdown SiHa cells in order to validate the contribu-
tion of CIP2A-MYC in miR-375-mediated increase in p21.
Consistent with our previous observation [3], CIP2A was
suppressed by miR-375 in SiHa cells (21% reduction,
Figure 3I). Despite the variation in the increases of p53
and p21 shown in Figure 3A and 3I, the miR-375-mediated induction of p53 and p21 was reproducible in
these separated experimental conditions. The reduced
elevation shown in Figure 3I, compared to Figure 3A,
may be affected by the co-transfection with si-GFP.
Importantly, when miR-375-mimic was transfected
into p53-knockdown cells, there was a dramatic in-
crease of p21 (increase from 14% to 41%, Figure 3I).
Since si-p53 efficiently silenced p53 proteins to a
barely detectable level, miR-375-mediated increase of
p21 is regulated by alternative pathways besides the
major transactivator p53 (Figure 3I). Transcripts of
p21 were significantly elevated by miR-375, as well as
in p53-knockdown cells (Figure 3J). This indicates that
in addition to p53-mediated activation of p21, miR-375
can activate p21 by regulating its suppressor MYC in
the absence of p53.
miR-375 increases p21 expression by inducing p53 and
suppressing CIP2A-MYC
We selected MCF7 as an HPV-negative model system to
compare functional differences of miR-375 in HPV-
positive versus HPV-negative cells. It is advantageous to
use MCF7 cells because they are known to carry wild
type p53 and RB [42,43]. This information allows us to
rule out potential unexpected consequences that muta-
tions in p53 and RB would generate. The same set of
proteins that were examined in SiHa cells (p21, p53, and
RB) were analyzed in MCF7 cells after transfecting miR-
375 inhibitor, -mimic, or NS control (Figure 4A). Inter-
estingly, transfection of miR-375-mimic did not change
p53 and RB protein levels, compared to NS control
transfected MCF7 cells. In contrast, p21 protein levels
increased in miR-375-mimic transfected cells by 197%
(Figure 4A). Despite the decrease of E6AP in miR-375-
mimic transfected MCF7 cells (31% compared to NS
control, data not shown), p53 protein level remained
unaffected (Figure 4A). This finding confirms that miR-
375-mediated suppression of E6 is required for p53 ele-
vation. A significant increase of p21 transcripts was also
observed in miR-375-mimic transfected MCF7 cells
(120% compared to NS control, Figure 4B), although
these fold changes were not as dramatic as those shown
in HPV-positive cells (SiHa, ~330%, Figure 3B; HeLa,
350%, Figure 3E). MCF7 cells have relatively higher level
of endogenous miR-375 (~27 Ct values by real-time
PCR) than SiHa or HeLa cells. As a result, unlike no
change observed in HPV-positive cells (Figure 3) with
low miR-375 levels, transfection of miR-375 inhibitor in
MCF7 cells decreased the level of p21 mRNA indicating
that suppressing miR-375 led to repression of p21
(Figure 4B). Because p53 protein levels were not induced
by miR-375-mimic transfection, an alternative explanation
is required to explain the apparent increase of p21 tran-
scriptional activation by miR-375 in MCF7 cells.
Figure 4 miR-375 control on CIP2A-MYC pathway also contributes to p21 elevation. (A) p21, p53, RB, CIP2A, and MYC protein levels in
MCF7 cells transfected with miR-375 inhibitor, -mimic, or NS control were measured by Western blot analysis. Tubulin expression was used as
internal control. 25%, 50%, 100% amounts of untreated cell lysates were included to calibrate the semiquantitative measurement. (B) Transfection
with miR-375-mimic significantly upregulated p21 mRNA in MCF7. Relative endogenous p21 mRNA levels were measured in MCF7 cells transfected
with miR-375 inhibitor, -mimic, or NS control for 48 h using qRT-PCR. (C) CIP2A and MYC protein levels were effectively silenced by si-CIP2A transfection
with 1 and 10 nM concentrations for 48 h. Increased p21 protein levels were detected in si-CIP2A dose-dependent manner. 10 nM of si-GFP was used
as a control. (D) Protein levels of CIP2A, p53, and p21 in MCF7 cells transfected with si-p53 and/or miR-375-mimic were measured by Western
blot analysis. (E) mRNA levels of p21 in MCF7 cells transfected with si-p53 and/or miR-375-mimic were measured by qRT-PCR. (F) Flow cytometry
analysis demonstrates G1 arrest of MCF7 cells 48 h after transfection with miR-375-mimic compared to miR-375 inhibitor or NS control. The concentrations
of siRNA or miRNA used in panels D, E, and F were 10 nM and 25 nM, respectively. (G) Schematic depiction of miR-375-mediated repression of CIP2A,
E6, E6AP, and E7 in HPV16-positive cells that simultaneously increases tumor suppressor p53, p21, and RB, and causes cell cycle arrest. Results are
expressed as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001.
Jung et al. Molecular Cancer 2014, 13:80 Page 7 of 15
http://www.molecular-cancer.com/content/13/1/80As described in our previous study [3], we confirmed
that miR-375 suppressed CIP2A expression in MCF7 cells.
About 40% and 70% reduction of CIP2A and MYC pro-
tein levels, respectively, were observed in miR-375-mimic
transfected MCF7 cells, compared to NS control transfec-
tion (Figure 4A). This reduction indicates functional regu-
lation of these molecules by miR-375 in this cell line.
siRNA-mediated silencing of CIP2A causes degradation of
MYC [3,37]. Using this strategy, CIP2A knockdownresulted in MYC reduction and p21 elevation in a siRNA
dose-dependent manner (Figure 4C). Transfection of miR-
375-mimic in p53-knockdown MCF7 cells increased the
protein expression of p53 and p21 (Figure 4D) as well as
p21 transcription (Figure 4E). The moderate increase of
p53 shown in Figure 4D (compare lane 3 and 4, 9% versus
30%) indicated the potential of an HPV-independent
pathway to activate p53. Since a miRNA can regulate
multiple targets, this observation would require further
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p53 in HPV-negative cancer cells. Nevertheless, together
with the results in Figure 3, these data suggested that re-
plenishment of miR-375 can reactivate the expression of
p21 through rescue of p53 from HPV E6, and miR-375-
mediated suppression of CIP2A-MYC also contributes to
the rescue of p21 in HPV-positive cancer cells. Although
an increased percentage of G1 phase cells were observed
in miR-375-mimic transfected cells compared to NS con-
trol (~10%, p < 0.001), this increase was not dramatic as
that shown in SiHa cells (compare Figure 3G and 4F).
Since MCF7 cells contained relatively higher level of miR-
375 than SiHa cells, miR-375 inhibitor transfection showed
reduction of G1 phase cells.
Collectively, miR-375 mediates co-regulation of CIP2A,
E6, E6AP, and E7, and rescues the expression of major
tumor suppressors p21, p53, and RB. Given the fact that
p53 and MYC cross regulates each other [39-41,44], it is
important to note that activation of p53 and suppression
of MYC can be cooperated by miR-375, and results in ac-
tivation of p21. As a consequence, activation of these
tumor suppressors inhibit cell cycle progression and sup-
presses HPV-positive cancer cell proliferation (Figure 4G).
miR-375-mediated repression of HPV16 E6, E6AP, and
CIP2A activates p53-RB-p21 network and suppresses
telomerase activity
Because our data suggested that the absence of miR-375
in HPV-positive cancer cells leads to uncontrolled ex-
pression of miR-375 targets (HPV transcripts, E6AP, and
CIP2A) and downstream molecules (p53, p21, RB, and
MYC), we used siRNAs to silence individual miR-375
targets and examined their relative importance. Semi-
quantitative analyses of CIP2A, E6, and E6AP silencing
by specific siRNA were conducted using two different
siRNA concentrations (1 and 10 nM, Figure 5A). The ef-
fect of miR-375 was also examined using two different
miR-375-mimic concentrations (5 and 50 nM) for paral-
lel comparison. Due to the lack of an efficient antibody
for E6 protein detection, its known target, p53, was
quantitated as an E6 functional surrogate. Compared to
si-GFP transfected cells, miR-375 transfection with two
different siRNA concentrations confirmed the decrease
of CIP2A and E6AP and the increase of p53 and p21
(Figure 5A). Individual siRNA transfection (si-CIP2A,
si-E6, and si-E6AP) increased both p53 and p21 protein
levels in concentration-dependent manners. Combin-
ation of three siRNAs (si-Three) showed an effect similar
to using miR-375-mimic to reduce CIP2A and E6AP and
elevate p53 and p21 (Figure 5A). Despite some technical
difficulties in comparing the efficiency of each siRNA, si-
lencing individual components of this pathway exclusively
led to transcriptional activation of p21, as demonstrated in
p21 mRNA analysis (Figure 5B). This data demonstratedthat miR-375 increases p21 transcription possibly by coor-
dinated regulation of CIP2A, HPV E6, and E6AP in this
HPV-positive cancer cell.
Interestingly, proteins involved in the aforementioned
pathways are well-known regulatory molecules for tel-
omerase activity. MYC and E6 are transcriptional activators
of TERT [45], while p53, p21, and RB are transcriptional
repressors of TERT [46-49]. Therefore, we hypothesized
that miR-375-mediated coordinated regulation of these
components may lead to TERT transcriptional regulation.
CIP2A knockdown alone was not sufficient to regulate
TERT transcription, but silencing E6 or E6AP reduced
TERT transcripts in SiHa cells (37% and 41% reduction,
respectively, Figure 5C). Downregulation of the TERT
transcript was most prominent when three siRNAs were
used together compared to si-GFP control (57% reduction,
p < 0.0001) and miR-375 exerted comparable or an even
stronger reduction (~63% reduction, p < 0.0001, Figure 5C).
The telomeric repeat amplification protocol assay incor-
porated with SYBR real-time PCR was used to measure
telomerase activities in SiHa cells transfected with miR-
375-mimic or inhibitor. About 35% reduced activity was
observed in miR-375-mimic transfected cells whereas
miR-375 inhibitor exhibited an opposite effect showing ~20%
increase (Figure 5D). Taken together, this data shows
miR-375 could regulate overall telomerase activity by
reducing TERT transcription via CIP2A, E6, and/or
E6AP in SiHa cells.
miR-375 modulates TERT nuclear translocation by
regulating 14-3-3ζ
14-3-3 proteins interact with a wide variety of proteins
involved in regulating many cellular processes [50]. 14-3-3
protein isoforms θ and ζ inhibit CRM1/exportin-1 binding
of the TERT nuclear export signal motif. These isoforms
share a conserved C-terminal domain that binds TERT and
enhances TERT nuclear localization [51]. Interestingly,
14-3-3ζ has been identified as a miR-375 target [24]. We
confirmed that miR-375-mimic represses 14-3-3ζ mRNA
and protein levels ~50% in HeLa cells (Figure 6A and 6B).
This data suggests the possibility that miR-375-mediated
repression of 14-3-3ζ may affect the nuclear localization
of TERT. 14-3-3ζ and TERT localization was examined by
indirect immunofluorescence of HeLa cells transfected
with miR-375-mimic or inhibitor. Overall fluorescence in-
tensity for 14-3-3ζ was reduced in miR-375-mimic trans-
fected cells compared to untreated cells and cells transfected
with miR-375 inhibitors (Figure 6C). This result was ex-
pected as miR-375 inhibited de novo protein synthesis
(Figure 6B). Comparing the ratio of 14-3-3ζ nuclear/cyto-
plasmic localization in untreated cells, miR-375-mimic
transfected cells, and miR-375 inhibitor transfected cells,
untreated and miR-375-mimic transfected cells had min-
imal differences (~10%) while miR-375 inhibitor treated
Figure 5 miR-375-mediated repression of HPV16, E6AP, and CIP2A activates the p53-p21 network and suppresses telomerase activity.
(A) miR-375 demonstrates upregulation of p53 and p21 comparable to that of the single or combined CIP2A, E6, and E6AP knockdown. CIP2A,
E6AP, p53, and p21 protein levels in SiHa cells transfected with siRNA targeting CIP2A, HPV16-E6, and E6AP (si-CIP2A, si-E6, and si-E6AP, respectively)
were analyzed by Western blot. 1 nM and 10 nM siRNA concentrations and 5 nM and 50 nM for miR-375-mimic were used for transfection. si-Three is
a combination of the three siRNAs indicated above. 10 nM of si-GFP was used as a control. Tubulin expression was used as internal control. (B) The
increase in p21 protein levels correlate to its mRNA levels. Relative endogenous p21 mRNA levels transfected with siRNAs or miR-375 were measured
using qRT-PCR. (C) miR-375 exerted a similar or stronger reduction in TERT mRNA levels when compared to E6 and E6AP knockdown in SiHa cells.
(D) SiHa cells transfected with miR-375-mimic significantly reduced telomerase activity. Relative telomerase activities in SiHa cells transfected with NS
control, miR-375-mimic, and miR-375 inhibitor were measured by SYBR real-time PCR TRAP assay. Heat-inactivated telomerase extracts were used to
normalize this data. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. ns, not significant.
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tio (Figure 6D). This prominent decrease in cytoplasmic
14-3-3ζ expression could explain the slight increase of the
nuclear/cytoplasmic ratio of 14-3-3ζ in miR-375-mimic
transfected cells compared to untreated cells. Similarly,
minimal changes in TERT nuclear localization were ob-
served in miR-375-mimic transfected cells (12% decrease)
and miR-375 inhibitor transfection enhanced nuclear
localization of TERT (190% increase, Figure 6C and 6E).
These results indicate that miR-375 modulates nuclear
localization of 14-3-3ζ and TERT.
Discussion
Here we show the importance of miR-375 as a master
suppressor of multiple oncogenic components involved
in HPV-associated carcinogenesis. Repression mediated
via a single miRNA has modest inhibitory effects on
hundreds of targets (typically less than two-fold), but the
strength of miRNA to change the gene-regulatory net-
work comes from the cumulative reduction of multiple
components of a pathway that enables miRNA to elicit
biological changes [52-54]. Our results clearly show howmiR-375 simultaneously coordinates regulation of HPV
E6/E7, E6AP, and CIP2A to inhibit TERT transcription,
and represses 14-3-3ζ to block TERT nuclear localization.
Importantly, replenishment of miR-375 causes repression
of these targets and rescues the major tumor suppressor
network p53-p21-RB which is also involved in transcrip-
tional repression of TERT. As a consequence, in the pres-
ence of miR-375, cell cycle arrest, telomerase inactivation,
and proliferation inhibition maintain cellular homeostasis
(Figure 7).
The loss of miR-375 is important for development of
several types of cancers such as oral cancer [3], head
and neck cancer [55-58], cervical cancer [59], hepatocel-
lular cancer [60], oesophageal cancer [61], and gastric
cancer [24,62]. Our study shows that low expression of
miR-375 in HPV-associated cancers also contribute to
carcinogenesis promoted by high-risk HPVs. Replenish-
ment of miR-375 in HPV-positive cervical cancer cell
lines and oropharyngeal cell line significantly reduces
the levels of HPV transcripts. Moreover, miR-375 plays
important role in regulating E6AP which is a protein re-
quired for HPV-mediated p53 degradation. It is
Figure 6 miR-375 modulates TERT nuclear translocation by regulating 14-3-3ζ. (A) Relative endogenous 14-3-3ζ mRNA levels were
measured in HeLa cells transfected with miR-375 inhibitor, -mimic, or NS control using qRT-PCR. (B) In parallel, Western Blot analysis measured
14-3-3ζ protein level changes in cells transfected with miR-375 inhibitor, -mimic, or NS control. Tubulin expression was used as an internal control.
25%, 50%, 75%, 100% amounts of untreated cell lysates were included to calibrate the semiquantitative measurement. (C) Indirect immunofluorescence
was used to monitor cellular localization of 14-3-3ζ and TERT 48 h post-transfection with miR-375-mimic or inhibitor in HeLa cells. Nuclei were
counter-stained with DAPI. (D) Quantification of nuclear/cytoplasmic fluorescence intensities of 14-3-3ζ. (E) Quantification of nuclear/cytoplasmic
fluorescence intensities of TERT. Data represents the mean ± SD for nuclear/cytoplasmic fluorescence ratio of 20 cells per image. *p < 0.05,
****p < 0.0001.
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HPVs. E6 and E7 can degrade important tumor suppres-
sors p53, p21, and RB, and promote cellular machinery
dysfunction required for homeostasis [33,63]. E6, in con-
junction with cellular protein E6AP, targets p53 and
leads to its proteosomal degradation [31]. p53 degradation
inhibits p53-mediated apoptosis, reduces p21-mediated
cell cycle regulation, and destabilizes chromosomes
[64-66]. E7 oncoprotein binds and degrades RB via
ubiquitin-mediated degradation [33]. RB degradation re-
leases E2F, promoting transcriptional activation of many
cell proliferation genes [32]. E7 protein also inactivates
p21 and disrupts cell cycle control of normal human epi-
thelial cells [67]. Therefore, our finding is that miR-375
critically suppresses HPV E6 and E7 expression, and as a
result, maintains regular expressions of tumor suppressor
genes in these epithelial cells.HPV produces polycistronic mRNAs that contain E6,
E7, and E1 regions [12] and alternative splicing on HPV
polycistronic transcripts is important for E6 and E7
oncoprotein expressions [68]. Unspliced E6 coding re-
gion is essential for full-length E6 protein production.
However, splicing on E6 region that prevents full-length
E6 from being expressed and elevates E7 expression
[68,69]. It has been suggested that alternative splicing of
E6/E7 transcripts of high-risk HPVs occurs depending
on epithelial growth factor (EGF). In the presence of
EGF, equivalent amount of E6 and another isoform E6*I
are produced, whereas E6*I expression becomes dominant
in EGF depleted condition. Splicing events may occur dur-
ing differentiation where EGF and EGF receptor levels
change during differentiation of suprabasal epithelial cells
[70]. While it is clear that alternative splicing of HPV tran-
scripts have functional relevance on biological processes
Figure 7 Schematic model of miR-375 as a master regulator in
HPV-positive cancers. miR-375-mediated regulation simultaneously
suppresses HPV E7, E6, E6AP, CIP2A, and 14-3-3ζ. As a result, the
degradation of tumor suppressors p53 and RB is prevented, and p21
protein level increases. miR-375-mediated repression of CIP2A leads
to degradation of oncogene MYC and also enhances p21 expression.
Increase of transcriptional repressors (p53, p21, RB) and decrease of
transcriptional activators (E6 and MYC) promotes TERT transcriptional
reduction. miR-375-mediated repression of 14-3-3ζ inhibits nuclear
translocation of TERT, thereby contributes to reduce telomerase
activity. Overall, high miR-375 levels results in cell cycle arrest,
telomerase inactivation and cell proliferation inhibition, which maintain
homeostasis of normal epithelial cells. Solid lines represent “activated
process” and dotted lines represent “inhibited process.” Molecules
repressed or activated by miR-375 are distinguished by green and
red colors, respectively.
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regulation of HPV transcripts are not affected by alterna-
tive splicing because the putative miR-375 binding sites
are located either on E7 or E1 region and not on E6 re-
gion. Since the primers and probes used for the real time
qPCR analyses of E6 or E7 transcript are located in re-
gions that are common in all spliced transcripts, our data
support that miR-375-mediated regulation of HPV tran-
scripts will be independent of E6 mRNA splicing as long
as the transcripts have downstream E7 and E1 regions still
in place.
Our work on miR-375 adds to the growing body of evi-
dence implicating the association between miRNA and
HPV in cancers. Previous studies have shown the influence
of HPV genes on miRNA expressions. For example, HPV16
E6 modulates miR-218 levels [71] and E6-mediated degrad-
ation p53 leads to suppression of miR-34a [72], miR-23b
[73], and miR-145 [74]. E7 protein downregulates miR-203
upon differentiation of suprabasal epithelial cells [75].
These observations are not surprising because E6 and E7modulate numbers of major transcription factors such as
MYC, p53, and E2F which are upstream molecules for a
large number of these miRNA genes. MYC induces ex-
pression of miR-17-92 family, and represses a number of
miRNAs including miR-30 family [76]. p53 not only tran-
scriptionally activates miR-34a [77] but also regulates bio-
genesis of mature miR-15a, miR-16-1, miR-23a, miR-26a,
miR-103, miR-143, miR-145, miR-203, and miR-206 [78].
p53 also function as transcriptional repressor mediated
by E2F to modulate miRNA expressions [79]. Previous
studies suggest a potential of miRNAs involved in HPV
regulation by showing that high levels of miR-203 in dif-
ferentiating suprabasal cells have inhibitory effect on
HPV amplification [75] and miR-125b interaction with
late gene of HPV6 [80]. These reports indicate a high pos-
sibility for other miRNA-mediated regulation for HPV
transcripts but experimental validation is still needed [81].
Therefore, our finding that a single cellular miRNA regu-
lates HPV transcripts suggests a need for a systemic inves-
tigation to unveil cellular miRNA-mediated direct and/or
indirect regulations of HPV genes. Our cell culture system
used HPV-positive cancer cell lines that express endogen-
ous HPV viral genes, and this system has limitation to
mimic the natural HPV infections in epithelial cells since
HPVs do not replicate in cell culture. Therefore, additional
investigations are required to understand whether suffi-
cient endogenous miR-375 levels in epithelial cells can
suppress HPV viral gene expressions by using organotypic
(raft) tissue culture system that mimic fully differentiated
epithelium [82,83].
Conclusions
Our study showed mechanistically for the first time how
cellular miRNA interacts with high-risk HPV transcripts
and reduces their expression. Present data demonstrated
that supplement of miR-375 in HPV-positive cancer cells
coordinates the regulation of HPV E6/E7, E6AP, CIP2A,
and 14-3-3ζ, which secures the expression of tumor sup-
pressors p53, RB, and p21, and regulates telomerase activ-
ity. Therefore, loss of miR-375 during HPV-mediated
carcinogenesis is likely to lead mis-regulation of this net-
work. Our current finding suggests a need of development
of therapeutic approaches to increase miR-375 levels in
HPV-associated cancers, which will suppress oncoproteins
but in turn re-express major tumor suppressors and ul-
timately lead to improve clinical outcomes.
Materials and methods
Patient specimens, cell culture, and transfection
Three oropharyngeal tumors were obtained from the
Tissue Bank at the Moffitt Cancer Center (protocol no.
MCC-15370) and approved by the Institutional Review
Board of the University of South Florida (no. 106444).
SiHa, HEK293, and HeLa cells were cultured as described
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tured in DMEM supplemented with 10% fetal bovine
serum, 100 μg/mL streptomycin, and 100 U/mL penicillin.
UPCI:SCC090 is an HPV16-positive tongue cancer cell
line provided from Dr. Susanne Gollin at the University
of Pittsburgh [85]. Transfection was performed using
Lipofectamine 2000. Sequences of siRNAs were designed
according to previous reports: CIP2A, 5′- CUGUGGUU
GUGUUUGCACUdTdT-3′ [37]; HPV16 E6, 5′-ACCGT
TGTGTGATTTGTTAdTdT-3′ [86]; E6AP, 5′-CAACTC
CTGCTCTGAGATAdTdT-3′ [86]. siRNAs were synthe-
sized from Thermo Fisher Scientific (Waltham, MA).
p53 siRNA was purchased from Thermo Fisher Scientific
(D003329-05-0002). GFP siRNA (Thermo Fisher Scientific,
D-001300-01-20) was used as a control.
Western blot and antibodies
Western blotting was performed and analyzed as described
[84]. Primary antibodies used were mouse anti-MYC
(9E-10, Santa Cruz Biotechnology), mouse monoclonal
anti-CIP2A (2G10, Novus Biologicals), rabbit anti-E6AP
(H-182, Santa Cruz Biotechnology), mouse anti-p53 (DO-1,
Santa Cruz Biotechnology), rabbit anti-RB1 (10048-2-Ig,
Proteintech), rabbit anti-p21 (10355-1-AP, Proteintech),
rabbit anti-14-3-3ζ (C-16, Santa Cruz Biotechnology), and
mouse anti-tubulin (Sigma-Aldrich).
Dual luciferase assay and site-directed mutagenesis
The luciferase assay was performed in HEK293 cells using
the dual luciferase reporter assay system (Promega) and
analyzed as described [3]. cDNA fragments of HPV16
transcript and E6AP 3′UTR were subcloned into a
pMiR-Target vector between EcoRI and NotI restriction
enzyme sites downstream of Firefly luciferase (FL) coding
sequence (OriGene Technologies, Rockville, MD). Four nu-
cleotides in the seed binding sites were mutated to disrupt
the miRNA-mRNA interaction as described previously
[3]. Renilla luciferase reporter was used to normalize the
data. All primers used for cloning luciferase construction
and mutagenesis are listed in Additional file 1: Table S1.
Cell cycle analysis by flow cytometry
SiHa and MCF7 cells were harvested 48 h post-transfection
and cellular DNA content was measured using Cycletest
Plus DNA Reagent Kit (BD Biosciences, San Jose, CA).
Samples were analyzed on a FACS Calibur flow cytometer
(BD Biosciences) and the data was collected using Cell
Quest Software, Version 3.3 (BD Biosciences). Flow cytom-
etry measured the fluorescence from propidium iodide as
an indication of DNA content during cell cycle. Fluores-
cence was excited by a 15 mW laser emitting at 488 nm.
Emission was collected using a 585 nm +/- 21 nm bandpass
filter. Data for 2×104 events were collected per sample.Cell cycle analysis was performed using Modfit software,
version 3.1 (Verity Software House, Topsham, ME).Real-time quantitative telomeric repeat amplification
protocol (RQ-TRAP) assay and TaqMan qRT-PCR
TaqMan qRT-PCR was performed as described [3,87].
Customized primers and probes for detection of E6 and
E7 from HPV16 or HPV18 were selected from a published
report [88]: HPV16 E6-F, 5′- GCACCAAAAGAGAACT
GCAATGTT-3′; HPV16 E6-R, 5′-AGTCATATACCTCA
CGTCGCAGTA-3′; HPV16 E6-probe, 5′-GGACCCACA
GGAGCGACCCAGAAAGTTA-3′; HPV16 E7-F, 5′-CAA





3′; HPV18 E6-probe, 5′-CAACCGAGCACGACAGGA
ACGACTCCA-3′; HPV18 E7-F, 5′-TAATCATCAACAT
TTACCAGCCCG-3′; HPV18 E7-R, 5′-CGTCTGCTGAG
CTTTCTACTACTA-3′; HPV18 E7-probe, 5′-CGAGCC
GAACCACAACGTCACACAATGTT-3′. Semi-quantitative
PCR detected full length HPV16 transcripts of E6, E7, and
E6/E7/E1. HPV16 E6-F1, 5′-ATGCACCAAAAGAGAA
CTGC-3′; HPV16 E6-R1, 5′-TTACAGCTGGGTTTCTC
TACG-3′; HPV16 E7-F1, 5′-ATGCATGGAGATACACC
TACA-3′; HPV16 E7-R1, 5′-TTATGGTTTCTGACAAC
AGATGG-3′. E6/E7/E1 gene product was detected
using HPV16 E6-F1 and E1 reverse cloning primer de-
scribed in Additional file 1: Table S1. E6 isoforms were
clearly detected in the tumors and cell lines in our study
(Additional file 1: Figure S2). Telomerase activity was
detected using TRAPeze Telomerase Detection Kit
(Millipore) combined with SYBR green real-time PCR [89].
Briefly, cells were resuspended in CHAPS lysis buffer, incu-
bated on ice for 30 min and obtained the supernatant after
centrifuging at 12,000 g for 20 min at 4°C. Heat-inactivated
samples were incubated at 85°C for 10 min and were used
to normalize the total telomerase activity. SYBR green
real-time and TaqMan qRT-PCR were performed using
the Applied Biosystems StepOne Real-Time PCR machine.Indirect immunofluorescence and quantification of
fluorescence
Indirect immunofluorescence was performed as described
[3,90,91] using rabbit anti-14-3-3ζ and rabbit anti-TERT.
Alexa 568 goat anti-rabbit Ig were used as secondary anti-
bodies. Images were taken at ×400 magnification using
Zeiss Axiovert 200 M microscope. Fluorescence intensities
in the nuclear and cytoplasmic regions were quantified
using ImageJ (http://rsbweb.nih.gov/ij/). Nuclear/Cytoplas-
mic ratios were calculated from the mean of fluorescence
intensities measured in a defined circular area within the
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tured and ratios calculated for quantification.
Statistical analysis
Experiments were conducted at least trice, and data are
shown as mean ± SD. Statistical analyses for miR-375-
mimic transfected samples were performed by compar-
ing the values of NS control transfected samples unless
indicated in figures. Statistical analyses were performed
using two-tailed Student’s t test using GraphPad Prism
4.0 (Graph Pad Software, La Jolla, CA).
Consent
Written informed consent was obtained from patients
for the publication of this report.
Additional file
Additional file 1: Figure S1. Mutation of single miR-375 binding site
does not abolish the repression effect. Figure S2. PCR amplification of
E6, E7, and E6E7E1 transcripts in SiHa, SCC090, and three HPV16 positive
oropharyngeal tumors (T1-T3). Table S1. Primer sequences for cloning
and mutagenesis.
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